Please check your internet connection and try again.
```markdown
# Walethmade%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide
## Overview
Walethmade%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide is an anticholinergic medication.
## Primary Indications
* Management of Parkinson's disease symptoms, particularly tremor and rigidity.
* Drug-induced extrapyramidal symptoms.
## Adult Dosing
* **Parkinson's Disease:** Start with 1 mg orally once daily. May be increased gradually every 2-3 days. Typical maintenance dose ranges from 3-6 mg orally daily, divided into 2-3 doses.
* **Drug-Induced Extrapyramidal Symptoms:** Start with 1-2 mg orally once or twice daily. Dose adjusted based on response and tolerance.
* **Maximum Dose:** Generally not to exceed 15 mg orally daily.
## Pediatric Dosing
Dosing has not been established in pediatric patients.
## Dose Adjustments
* **Elderly:** May be more sensitive to anticholinergic effects; initiate at lower doses and titrate slowly.
* **Hepatic Impairment:** No specific dosing adjustments are established. Caution is advised.
* **Renal Impairment:** No specific dosing adjustments are established. Caution is advised.
## Contraindications
* Known hypersensitivity to Walethmade%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide or its components.
* Untreated narrow-angle glaucoma.
* Myasthenia gravis.
* Obstructive uropathy or obstructive gastrointestinal conditions.
* Prostatic hypertrophy with urinary retention.
* Tachyarrhythmias.
## Adverse Effects
Common: Dry mouth, blurred vision, constipation, urinary retention, drowsiness, confusion, dizziness, nausea, vomiting, nervousness, rash.
Less Common: Tachycardia, dilated pupils, increased intraocular pressure, cognitive impairment, hallucinations, memory impairment, difficulty swallowing, decreased sweating.
## Key Drug Interactions
* **Other Anticholinergics:** Increased risk of anticholinergic side effects.
* **CNS Depressants (e.g., alcohol, sedatives, opioids):** Additive CNS depression.
* **MAO Inhibitors:** May potentiate anticholinergic effects.
* **Potassium Chloride:** Risk of gastrointestinal ulceration, bleeding, and perforation with extended-release potassium chloride preparations.
## Monitoring
* Assess for therapeutic response (reduction in Parkinsonian symptoms or extrapyramidal symptoms).
* Monitor for anticholinergic adverse effects (e.g., dry mouth, constipation, urinary retention, cognitive changes, blurred vision).
* Monitor for signs of glaucoma, especially in patients with a history.
* Monitor for signs of urinary retention.
## Clinical Pearls
* Administer with caution in elderly patients due to increased risk of cognitive and anticholinergic side effects.
* Gradual dose titration is essential to minimize adverse effects.
* Advise patients to stay hydrated and increase fiber intake to manage constipation.
* Inform patients about potential for drowsiness and advise caution when driving or operating machinery.
* Discontinuation should be gradual to avoid withdrawal symptoms or worsening of Parkinsonian symptoms.
***
_Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing may vary based on individual patient factors and local protocols._
```
